CIMA Sciences LLC is a biotechnology company based in the US, dedicated to revolutionizing how people diagnose and treat diseases with non-invasive diagnostic technology. Established in March 2022 in San Antonio, Texas, CIMA Sciences is the joint venture between the Spanish pharmaceutical company, Laboratorios Rubió, and leading experts in the field of Nonalcoholic Fatty Liver Disease (NAFLD). Having launched OWLiver® and Liposcale® in the US, CIMA Sciences works towards completely changing how healthcare providers diagnose in the medical fields related to liver and cardiovascular risk. For this purpose, we offer a non-invasive, cost-effective, and reliable approach to diagnosing the disease. Our cutting-edge technology aims to provide physicians with the tools they need to assess, diagnose, and care better for their patients. Our commitment is to lead the way in non-invasive diagnostic technology, providing innovative solutions to the most challenging healthcare issues. We look forward to making a lasting impact in the US healthcare industry.
